Canine Atopic Dermatitis: Diagnosis and Multimodal Management

Canine atopic dermatitis (CAD) is a chronic, genetically predisposed inflammatory and pruritic skin disease requiring systematic diagnosis and multimodal management. This article provides veterinarians with an evidence-based framework for diagnosing CAD using validated clinical criteria and constructing individualized treatment plans combining allergen-specific immunotherapy, antipruritic pharmacotherapy, topical therapy, and environmental control.

At a Glance: Canine Atopic Dermatitis Diagnosis and Management

Pathophysiology and Clinical Presentation

Current Understanding of CAD Pathogenesis

The International Committee on Allergic Diseases of Animals (ICADA) 2023 updated definition and pathogenesis review articles describe CAD as a complex disease involving skin barrier dysfunction, immune dysregulation, and environmental allergen exposure (PubMed: 38095285). The pathogenesis includes epidermal barrier defects that allow allergen penetration, a Th2-dominant immune response, and altered skin microbiome composition. Genetic predisposition is well established, with breed-specific risk factors documented in breeds including West Highland White Terriers, Labrador Retrievers, Golden Retrievers, French Bulldogs, and Boxers.

The immune response in CAD involves allergen-specific IgE production, mast cell degranulation, and recruitment of inflammatory cells. Cytokines including IL-4, IL-13, IL-31, and IL-33 drive pruritus and inflammation. The Janus kinase (JAK)-STAT signaling pathway mediates the effects of multiple pruritogenic and proinflammatory cytokines, providing a therapeutic target for JAK inhibitors such as oclacitinib.

Clinical Signs and Lesion Distribution

CAD typically presents with pruritus affecting the face, ears, axillae, ventral abdomen, distal extremities, and perineal region. Primary lesions include erythema, papules, and excoriations. Chronic disease leads to lichenification, hyperpigmentation, alopecia, and secondary infections. The age of onset is usually between 6 months and 3 years, though some breeds may present earlier or later.

Pruritus is the hallmark clinical sign. Dogs may present with scratching, rubbing, licking, chewing, or head shaking. Secondary pyoderma and Malassezia dermatitis are common complications that exacerbate pruritus and require concurrent treatment.

Differential Diagnoses

Before diagnosing CAD, veterinarians must exclude other pruritic dermatoses. The primary differentials include:

• Flea allergy dermatitis
• Food-induced atopic dermatitis (adverse food reaction)
• Scabies (Sarcoptes scabiei infestation)
• Other ectoparasites (cheyletiellosis, pediculosis)
• Primary pyoderma or Malassezia dermatitis
• Contact dermatitis
• Cutaneous adverse drug reaction

The Merck Veterinary Manual provides comprehensive guidance on differential diagnosis of pruritic skin diseases in dogs (Merck Veterinary Manual: www.merckvetmanual.com/).

Diagnostic Approach

Favrot's Diagnostic Criteria

Favrot's criteria provide a validated clinical tool for diagnosing CAD. The criteria are divided into two sets.

Set 1 (for dogs with no breed predisposition):

• Onset of signs before 3 years of age
• Dog living mostly indoors
• Pruritus responsive to glucocorticoids
• Chronic or recurrent yeast infections
• Affected front paws
• Affected ear pinnae
• Non-affected ear margins
• Non-affected dorsolumbar area

Set 2 (for dogs with breed predisposition):

• Onset of signs before 3 years of age
• Dog living mostly indoors
• Pruritus responsive to glucocorticoids
• Affected front paws
• Affected ear pinnae
• Non-affected ear margins
• Non-affected dorsolumbar area

A diagnosis of CAD is considered when at least 5 of 8 criteria in Set 1 or at least 4 of 7 criteria in Set 2 are present, after excluding other pruritic dermatoses. The BMC Veterinary Research publication "Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification" provides additional diagnostic guidance (PubMed: 26260508).

Exclusion of Other Pruritic Dermatoses

Flea Allergy Dermatitis: Implement rigorous flea control for 6-8 weeks before concluding flea allergy is not contributing. Use veterinary-approved flea preventives on all pets in the household.

Food-Induced Atopic Dermatitis: Conduct an 8-week elimination diet trial using a novel protein or hydrolyzed protein diet. If pruritus resolves, perform dietary challenge to confirm. Food allergy can coexist with environmental allergies.

Scabies: Perform skin scrapings from affected areas (elbows, ear margins, ventral abdomen). Consider therapeutic trial with an appropriate acaricide if scrapings are negative but clinical suspicion remains.

Secondary Infections: Collect cytology samples from affected skin to identify bacteria and yeast. Treat infections before finalizing CAD diagnosis, as infections alone can cause pruritus.

Allergy Testing: Intradermal Testing and Serum IgE Testing

Allergy testing identifies environmental allergens for inclusion in allergen-specific immunotherapy. Testing is indicated after CAD diagnosis is confirmed and other pruritic dermatoses are excluded.

Intradermal Testing (IDT): IDT involves injecting small volumes of allergen extracts intradermally and assessing wheal formation. IDT requires specialized training, equipment, and allergen extracts. Results are interpreted subjectively based on wheal size and erythema compared to positive (histamine) and negative (diluent) controls. IDT is considered the reference standard for allergen identification.

Serum Allergen-Specific IgE Testing: Serum testing measures allergen-specific IgE antibodies using ELISA or other immunoassay methods. Advantages include no requirement for specialized equipment or drug withdrawal. However, serum testing may detect clinically irrelevant IgE, and results do not always correlate with IDT.

Both IDT and serum testing have limitations. Neither test alone diagnoses CAD, they identify allergens for immunotherapy. The decision to use IDT or serum testing depends on clinician preference, available resources, and patient factors.

CADESI-4 Scoring

The Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 is a validated tool for assessing skin lesion severity in dogs with CAD (PubMed: 24461108). The scoring system evaluates erythema, lichenification, and excoriation/alopecia at 20 body sites. Each lesion type is scored 0-3 (absent, mild, moderate, severe) at each site, yielding a total score range of 0-180.

CADESI-4 scoring provides objective documentation of disease severity and response to treatment. Regular scoring at each recheck visit guides treatment adjustments and documents treatment efficacy.

Multimodal Management Principles

Treatment Goals

The goals of CAD management are to:

• Control pruritus and improve quality of life
• Reduce skin lesion severity
• Minimize adverse effects of therapy
• Prevent disease flares and secondary infections
• Reduce reliance on glucocorticoids
• Address underlying immune dysregulation with ASIT

Multimodal Approach

CAD management requires a multimodal approach combining:

1. Allergen-specific immunotherapy (disease-modifying)
2. Antipruritic pharmacotherapy (symptom control)
3. Topical therapy (skin barrier support and infection control)
4. Environmental allergen avoidance
5. Management of secondary infections

The Journal of the American Veterinary Medical Association publication "Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs" provides current treatment recommendations (PubMed: 31067173).

Allergen-Specific Immunotherapy

Mechanism of Action

Allergen-specific immunotherapy (ASIT) involves administering gradually increasing doses of allergens to induce immunologic tolerance. The mechanism includes shifting the immune response from Th2 to Th1, inducing regulatory T cells, and increasing allergen-specific IgG antibodies. The Veterinary Immunology and Immunopathology publication "Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis" documents this immunologic shift (Elsevier: 10.1016/j.vetimm.2004.06.003).

Subcutaneous Immunotherapy (SCIT)

SCIT involves subcutaneous injections of allergen extracts, typically administered weekly during the induction phase and then at 2-4 week intervals during maintenance. Injection volumes and concentrations are determined by the prescribing veterinarian based on test results and patient response.

Induction Protocols: Rush protocols achieve maintenance dose in 1-2 days with multiple injections, while conventional protocols require 4-6 months of weekly injections. Rush protocols require hospitalization and monitoring for adverse reactions.

Maintenance Therapy: Maintenance injections are given every 2-4 weeks. Most dogs require lifelong therapy. Initial improvement may be seen within 3-6 months, with maximal benefit at 9-12 months.

Adverse Reactions: Local reactions (swelling, erythema at injection site) are common and usually self-limiting. Systemic reactions (urticaria, angioedema, vomiting, diarrhea, anaphylaxis) are rare but require immediate veterinary attention.

Sublingual Immunotherapy (SLIT)

SLIT involves administering allergen extracts under the tongue, typically daily. Advantages include ease of administration, no injections, and lower risk of systemic reactions. The Veterinary Immunology and Immunopathology publication "Food allergen-specific sublingual immunotherapy modulates peripheral T cell responses of dogs with adverse food reactions" documents immunologic effects of SLIT (Elsevier: 10.1016/j.vetimm.2019.05.003).

SLIT is available as aqueous solutions or dissolvable tablets. Dosing is typically daily, with allergen extracts held under the tongue for 1-2 minutes before swallowing.

Monitoring Response to ASIT

Response to ASIT is assessed using:

• Owner-reported pruritus scores (PVAS)
• CADESI-4 lesion scores
• Frequency of disease flares
• Need for rescue antipruritic medication
• Owner quality-of-life assessment

The Veterinary Immunology and Immunopathology publication "Effect of immunotherapy on the serum concentrations of allergen-specific IgG antibodies in dog sera" documents immunologic monitoring (Elsevier: 10.1016/0165-2427(89)90162-1).

Antipruritic Pharmacotherapy

Oclacitinib

Oclacitinib is a Janus kinase (JAK) inhibitor that blocks JAK1-dependent cytokine signaling, including IL-31, IL-4, IL-13, and other pruritogenic and proinflammatory cytokines. It is approved for control of pruritus associated with allergic dermatitis and atopic dermatitis in dogs.

Efficacy: Oclacitinib provides rapid pruritus relief, often within 24 hours. The publication "Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis" documents comparative efficacy (PubMed: 39757965).

Dosing: Oclacitinib is administered orally twice daily for 14 days, then once daily for maintenance. The chewable formulation may improve owner compliance, as documented in "Dog Owners' Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey" (Animals: 10.3390/ani14060952).

Adverse Effects: Common adverse effects include vomiting, diarrhea, and decreased appetite. Less common effects include urinary tract infections, demodicosis, and papillomas. The publication "Comparative evaluation of therapeutic efficacy of prednisolone and oclacitinib in amelioration of canine atopic dermatitis in Indian dog population" provides comparative safety data (Indian Journal of Animal Health: 10.36062/ijah.2026.13925).

Long-Term Safety Concerns: Prolonged oclacitinib use has been associated with potential adverse effects. The case report "Case Report of Hemangiopericytoma Development After Prolonged Use of Oclacitinib Maleate in a Dog with Atopic Dermatitis and Iatrogenic Hyperadrenocorticism" documents tumor development in a dog with prolonged oclacitinib use (International Journal of Zoology and Animal Biology: 10.23880/izab-16000605). The case report "Case Report: The potential association with polyglandular autoimmune syndrome in a dog following long-term oclacitinib therapy" documents development of primary hypoadrenocorticism and hypothyroidism in a dog receiving oclacitinib for 7 years (Frontiers in Veterinary Science: 10.3389/fvets.2025.1535272). The case report "A case of lingual lymphoma in a dog treated with oclacitinib" documents lymphoma development in a dog receiving oclacitinib (Journal of Veterinary Medical Science: 10.1292/jvms.24-0432).

Monitoring: Perform complete blood count, serum biochemistry, and urinalysis every 6-12 months in dogs receiving long-term oclacitinib. Monitor for signs of urinary tract infection, demodicosis, and neoplasia.

Lokivetmab

Lokivetmab is a caninized monoclonal antibody that binds to and neutralizes IL-31, a key pruritogenic cytokine. It is administered subcutaneously every 4-8 weeks.

Efficacy: Lokivetmab provides rapid pruritus relief, typically within 24-48 hours. Duration of effect varies between dogs, with some requiring dosing every 4 weeks and others maintaining control for 8 weeks.

Safety: Lokivetmab has a favorable safety profile. Adverse effects are uncommon and include injection site reactions, vomiting, and diarrhea. No long-term safety concerns have been identified.

Monitoring: Assess pruritus control at each injection visit. Adjust dosing interval based on return of pruritus.

Glucocorticoids

Glucocorticoids (prednisolone, prednisone, methylprednisolone) provide rapid and effective pruritus control but are associated with significant adverse effects with long-term use.

Indications: Glucocorticoids are appropriate for short-term flare control, initial therapy while awaiting response to other treatments, and in dogs where other therapies are contraindicated or unaffordable.

Adverse Effects: Polyuria, polydipsia, polyphagia, panting, muscle wasting, calcinosis cutis, urinary tract infections, diabetes mellitus, and iatrogenic hyperadrenocorticism. The case report "Case Report of Hemangiopericytoma Development After Prolonged Use of Oclacitinib Maleate in a Dog with Atopic Dermatitis and Iatrogenic Hyperadrenocorticism" documents iatrogenic hyperadrenocorticism from glucocorticoid use (International Journal of Zoology and Animal Biology: 10.23880/izab-16000605).

Monitoring: Perform urinalysis and urine culture every 3-6 months in dogs receiving long-term glucocorticoids. Monitor for signs of hyperadrenocorticism.

Cyclosporine

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and cytokine production. It is approved for treatment of CAD in dogs.

Efficacy: Cyclosporine provides effective pruritus control, though onset of action is slower than oclacitinib or lokivetmab (2-4 weeks for initial response, 6-8 weeks for maximal effect).

Dosing: Cyclosporine is administered orally once daily. The microemulsion formulation (Atopica) has improved bioavailability.

Adverse Effects: Vomiting, diarrhea, gingival hyperplasia, papillomatosis, and hirsutism. Cyclosporine is metabolized by the liver and excreted in bile.

Monitoring: Perform complete blood count, serum biochemistry, and urinalysis every 6-12 months. Monitor for gingival hyperplasia and papillomas.

Topical Therapy

Topical therapy is an important adjunctive component of CAD management.

Shampoos: Antimicrobial shampoos (chlorhexidine, ketoconazole, miconazole) treat secondary pyoderma and Malassezia dermatitis. Ceramide-containing shampoos support skin barrier function.

Sprays and Spot-Ons: Topical glucocorticoid sprays (hydrocortisone aceponate) provide localized anti-inflammatory effect. Ceramide-containing spot-ons support skin barrier function.

Moisturizers: Humectant and emollient products improve skin hydration and barrier function.

Environmental Allergen Avoidance

Allergen Identification

Allergen identification through IDT or serum testing guides environmental avoidance strategies. Common environmental allergens include:

• House dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus)
• Pollens (grasses, trees, weeds)
• Molds
• Storage mites
• Insect allergens

Environmental Control Measures

House Dust Mite Avoidance: Use allergen-impermeable covers on mattresses and pillows. Wash bedding in hot water (130°F/54°C) weekly. Reduce indoor humidity below 50%. Remove carpeting and upholstered furniture where possible. Use HEPA air filters.

Pollen Avoidance: Keep dogs indoors during peak pollen times. Wipe paws and coat after outdoor exposure. Use air conditioning instead of open windows.

Mold Avoidance: Repair water leaks. Reduce indoor humidity. Clean moldy surfaces with appropriate products.

Management of Secondary Infections

Bacterial Pyoderma

Secondary bacterial pyoderma is common in CAD. Cytology identifies cocci bacteria. Treatment involves systemic antibiotics based on culture and sensitivity when possible. Topical antimicrobial therapy (chlorhexidine shampoos, sprays) is used for localized infections.

Malassezia Dermatitis

Malassezia overgrowth is common in CAD, particularly in skin folds and interdigital spaces. Cytology identifies yeast organisms. Treatment involves topical antifungal therapy (ketoconazole, miconazole shampoos) and systemic antifungal therapy (ketoconazole, itraconazole) for severe cases.

Acral Lick Dermatitis

Acral lick dermatitis (ALD) is a complication of chronic pruritus in CAD. The Veterinary Clinics of North America: Small Animal Practice publication "Diagnosis and Treatment of Canine Acral Lick Dermatitis" provides diagnostic and treatment guidance (PubMed: 30268424). ALD management requires addressing underlying pruritus, treating secondary infection, and behavioral modification.

Practical Implementation Steps

Step 1: Confirm Diagnosis

1. Take thorough history including age of onset, pruritus pattern, response to previous treatments, and environmental factors
2. Perform complete physical examination with dermatologic assessment
3. Apply Favrot's diagnostic criteria
4. Exclude flea allergy dermatitis with rigorous flea control
5. Conduct elimination diet trial for 8 weeks
6. Perform skin scrapings to exclude scabies
7. Collect cytology samples to identify secondary infections
8. Treat identified infections before finalizing CAD diagnosis

Step 2: Assess Disease Severity

1. Score pruritus using PVAS (0-10 scale)
2. Score skin lesions using CADESI-4
3. Document lesion distribution and severity
4. Assess owner perception of quality of life
5. Identify disease triggers and seasonal patterns

Step 3: Initiate Multimodal Treatment

1. Discuss treatment options with owner including goals, costs, and monitoring requirements
2. Initiate antipruritic therapy for immediate symptom control
3. Consider ASIT for disease modification
4. Implement environmental allergen avoidance measures
5. Prescribe topical therapy for skin barrier support
6. Treat secondary infections if present

Step 4: Monitor and Adjust

1. Schedule recheck visits at 2-4 week intervals during initial treatment
2. Repeat PVAS and CADESI-4 scoring at each visit
3. Adjust antipruritic therapy based on response
4. Monitor for adverse effects of medications
5. Assess response to ASIT at 3, 6, and 12 months
6. Perform laboratory monitoring as indicated

Step 5: Long-Term Management

1. Establish maintenance treatment protocol
2. Schedule recheck visits every 3-6 months
3. Monitor for disease flares and secondary infections
4. Adjust ASIT formulation if response is inadequate
5. Consider dose reduction of antipruritic medications during periods of low allergen exposure
6. Document treatment response and adverse effects in medical record

Records and Measurements

Essential Records

• Signalment and history
• Favrot's criteria assessment
• Results of diagnostic tests (skin scrapings, cytology, elimination diet trial)
• Allergy test results (IDT or serum IgE)
• CADESI-4 scores at each visit
• PVAS scores at each visit
• Treatment plan including medications, doses, and administration schedule
• Adverse effects and monitoring results
• Owner compliance assessment

Monitoring Parameters

Common Failure Patterns

Diagnostic Errors

• Failure to exclude food allergy before diagnosing CAD
• Inadequate flea control leading to misdiagnosis
• Failure to identify and treat secondary infections
• Overreliance on allergy testing for diagnosis instead of confirmation

Treatment Failures

• Inadequate dose or duration of ASIT
• Poor owner compliance with ASIT administration
• Failure to address environmental allergen exposure
• Inadequate treatment of secondary infections
• Development of adverse effects requiring treatment discontinuation
• Progression of disease requiring treatment adjustment

Monitoring Failures

• Inadequate frequency of recheck visits
• Failure to use objective scoring tools
• Inadequate laboratory monitoring for adverse effects
• Failure to document treatment response

Limitations and Safety Context

Limitations of Current Therapies

• ASIT requires 6-12 months for initial response and lifelong treatment
• Oclacitinib and cyclosporine require ongoing administration
• Glucocorticoids have significant adverse effects with long-term use
• Lokivetmab requires injection every 4-8 weeks
• No therapy provides complete cure

Safety Considerations

Oclacitinib: Monitor for urinary tract infections, demodicosis, papillomas, and neoplasia. The case report "Case Report of Hemangiopericytoma Development After Prolonged Use of Oclacitinib Maleate in a Dog with Atopic Dermatitis and Iatrogenic Hyperadrenocorticism" documents tumor development (International Journal of Zoology and Animal Biology: 10.23880/izab-16000605). The case report "Case Report: The potential association with polyglandular autoimmune syndrome in a dog following long-term oclacitinib therapy" documents autoimmune disease development (Frontiers in Veterinary Science: 10.3389/fvets.2025.1535272). The case report "A case of lingual lymphoma in a dog treated with oclacitinib" documents lymphoma development (Journal of Veterinary Medical Science: 10.1292/jvms.24-0432).

Glucocorticoids: Monitor for iatrogenic hyperadrenocorticism, diabetes mellitus, and urinary tract infections.

Cyclosporine: Monitor for gingival hyperplasia, papillomas, and gastrointestinal adverse effects.

Lokivetmab: Monitor for injection site reactions.

Professional Escalation Criteria

Refer to a veterinary dermatologist when:

• Diagnosis is uncertain after initial evaluation
• Response to treatment is inadequate after 6 months
• Adverse effects limit treatment options
• Severe or refractory disease
• Need for advanced diagnostic testing (IDT, skin biopsy)
• Need for specialized treatment (rush immunotherapy, allergen extract formulation)

Practical Decision Framework for Selecting and Sequencing Antipruritic Therapy in Canine Atopic Dermatitis

Selecting the appropriate antipruritic medication for a dog with confirmed CAD requires a structured decision process that accounts for disease severity, speed of onset needed, concurrent infections, owner compliance factors, cost constraints, and long-term safety monitoring. This section provides a practical framework for choosing between oclacitinib, lokivetmab, glucocorticoids, and cyclosporine, including sequencing strategies for flare management and maintenance therapy.

Initial Assessment Parameters for Drug Selection

Before selecting an antipruritic agent, document the following parameters at the initial visit using objective scoring tools. The Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 provides a validated measure of lesion severity (PubMed: 24461108). The pruritus Visual Analog Scale (PVAS) captures owner-reported itch severity on a 0-10 scale. Record both scores at baseline to establish a reference for treatment response assessment.

Essential baseline data points:

• CADESI-4 total score (range 0-180)
• PVAS score (0-10)
• Presence and type of secondary infection (bacterial, Malassezia, or both) confirmed by cytology
• Previous treatment history including response and adverse effects
• Owner's ability to administer oral medications versus preference for injectable therapy
• Financial constraints affecting treatment duration and monitoring frequency
• Concurrent medical conditions (renal disease, diabetes mellitus, hyperadrenocorticism, neoplasia history)

The Merck Veterinary Manual provides guidance on evaluating pruritic dogs and selecting appropriate therapies based on individual patient factors (Merck Veterinary Manual: www.merckvetmanual.com/dog-owners).

Decision Algorithm for First-Line Antipruritic Therapy

Scenario 1: Rapid pruritus control needed (within 24-48 hours) with no contraindications

For dogs requiring immediate relief from severe pruritus where rapid onset is the priority, oclacitinib or lokivetmab are appropriate first-line choices. Oclacitinib provides pruritus relief within 24 hours in most dogs, as documented in the comparative efficacy study of ilunocitinib and oclacitinib (PubMed: 39757965). Lokivetmab also provides rapid relief within 24-48 hours after subcutaneous administration.

Select oclacitinib when:

• Owner can administer oral medication twice daily for 14 days then once daily
• Dog does not have a history of seizures or neurologic disease
• No evidence of active demodicosis or generalized papillomatosis
• Owner understands the need for long-term monitoring including bloodwork every 6-12 months

Select lokivetmab when:

• Owner prefers injectable therapy over oral medication
• Dog is difficult to medicate orally
• History of poor compliance with daily oral medications
• Concern about potential adverse effects of JAK inhibition
• Owner can return for injections every 4-8 weeks

Scenario 2: Rapid pruritus control needed with contraindications to oclacitinib or lokivetmab

When oclacitinib and lokivetmab are contraindicated due to cost, availability, or specific patient factors, short-term glucocorticoid therapy may be appropriate. The case report documenting iatrogenic hyperadrenocorticism from prolonged glucocorticoid use highlights the importance of limiting glucocorticoid duration (International Journal of Zoology and Animal Biology: 10.23880/izab-16000605).

Use glucocorticoids only when:

• Short-term therapy is planned (less than 30 days)
• Other therapies are unavailable or unaffordable
• Dog requires immediate relief while awaiting response to other therapies
• No contraindications such as diabetes mellitus or hyperadrenocorticism exist

Document a clear plan for transitioning to a safer long-term therapy when initiating glucocorticoids.

Scenario 3: Slower onset acceptable with need for long-term maintenance

Cyclosporine is appropriate when a slower onset of action (2-4 weeks for initial response, 6-8 weeks for maximal effect) is acceptable. Cyclosporine is particularly useful for dogs that cannot receive oclacitinib due to seizure history or other contraindications, and when lokivetmab is not available or affordable.

Select cyclosporine when:

• Long-term maintenance therapy is the goal
• Owner can administer daily oral medication
• Dog does not have a history of gingival hyperplasia or papillomatosis
• Owner understands potential gastrointestinal adverse effects
• Monitoring for gingival hyperplasia and papillomas is feasible

Sequencing Strategy for Flare Management

Dogs with CAD experience disease flares requiring temporary intensification of therapy. Establish a written flare management plan at the initial visit.

Mild flare (PVAS increase of 1-3 points, no new lesions):

• Increase frequency of topical therapy (antimicrobial shampoo twice weekly)
• Add topical glucocorticoid spray to affected areas for 5-7 days
• Recheck in 7-10 days

Moderate flare (PVAS increase of 4-6 points, new lesions present):

• Increase oclacitinib to twice daily dosing for 7-14 days if on once daily maintenance
• Add short-term glucocorticoid therapy (prednisolone 0.5 mg/kg once daily for 5-7 days)
• Treat secondary infection based on cytology results
• Recheck in 7-14 days

Severe flare (PVAS increase of 7-10 points, widespread lesions, secondary infection):

• Initiate or increase glucocorticoid therapy (prednisolone 1 mg/kg once daily for 5-7 days, then taper)
• Treat secondary infection with appropriate systemic antibiotics or antifungals
• Consider adding lokivetmab if not already on therapy
• Recheck in 7 days

Document all flare episodes in the medical record including trigger identification when possible.

Comparison of Antipruritic Agents for Clinical Decision Making

Record System for Treatment Response Documentation

Implement a standardized record system to track treatment response and guide adjustments. The following template captures essential data at each recheck visit.

Treatment Response Record Template:

Instructions for use:

• Record PVAS and CADESI-4 at every visit
• Document all medications including dose, frequency, and route
• Note any adverse effects observed by owner or clinician
• Record cytology results if secondary infection suspected
• Document the plan for next visit including medication adjustments

The AAHA resources provide additional guidance on medical record keeping and treatment documentation (AAHA: www.aaha.org/resources).

Troubleshooting Common Treatment Failures

Failure Pattern 1: Inadequate pruritus control with oclacitinib

Possible causes and corrective actions:

• Subtherapeutic dose: Ensure dog is receiving correct dose based on body weight. Recheck body weight at each visit.
• Poor owner compliance: The chewable formulation may improve compliance as documented in the international survey of dog owners (Animals: 10.3390/ani14060952). Consider switching to chewable formulation if using film-coated tablets.
• Concurrent infection: Collect cytology and treat identified infections. Secondary pyoderma and Malassezia dermatitis exacerbate pruritus.
• Incorrect diagnosis: Re-evaluate for food allergy, scabies, or other pruritic dermatoses.
• Drug tolerance: Consider switching to lokivetmab or adding a second agent.

Failure Pattern 2: Loss of response to lokivetmab

Possible causes and corrective actions:

• Shortened duration of effect: Shorten dosing interval from 8 weeks to 4-6 weeks
• Concurrent infection: Treat secondary infections
• Disease progression: Consider adding ASIT for disease modification
• Incorrect diagnosis: Re-evaluate for other pruritic dermatoses

Failure Pattern 3: Adverse effects limiting therapy

For oclacitinib-related adverse effects:

• Gastrointestinal signs: Administer with food, consider dose reduction, or switch to lokivetmab
• Urinary tract infection: Treat infection, monitor urine culture, consider switching to alternative therapy
• Demodicosis: Treat demodicosis, consider switching to lokivetmab or cyclosporine
• Neoplasia concern: Discontinue oclacitinib, switch to lokivetmab or ASIT

The case report documenting hemangiopericytoma development after prolonged oclacitinib use in a dog with iatrogenic hyperadrenocorticism illustrates the importance of monitoring for neoplasia (International Journal of Zoology and Animal Biology: 10.23880/izab-16000605). The case report of lingual lymphoma in a dog treated with oclacitinib further supports the need for vigilance (Journal of Veterinary Medical Science: 10.1292/jvms.24-0432). The case report suggesting potential association between prolonged oclacitinib administration and polyglandular autoimmune syndrome recommends regular hormonal monitoring (Frontiers in Veterinary Science: 10.3389/fvets.2025.1535272).

For glucocorticoid-related adverse effects:

• Iatrogenic hyperadrenocorticism: Taper glucocorticoids, transition to safer long-term therapy
• Diabetes mellitus: Manage diabetes, discontinue glucocorticoids
• Urinary tract infection: Treat infection, monitor urine culture

For cyclosporine-related adverse effects:

• Gastrointestinal signs: Administer on empty stomach or with small amount of food, consider dose reduction
• Gingival hyperplasia: Monitor oral health, consider switching to alternative therapy
• Papillomatosis: Monitor lesions, consider switching to alternative therapy

Professional Escalation Criteria for Treatment Failure

Refer to a veterinary dermatologist when:

• No improvement in PVAS or CADESI-4 after 3 months of appropriate therapy
• Multiple drug failures due to adverse effects
• Need for rush immunotherapy or allergen extract formulation
• Suspected concurrent autoimmune skin disease
• Severe or refractory secondary infections
• Development of adverse effects requiring specialized management

The ACVIM provides resources for locating board-certified veterinary dermatologists (ACVIM: www.acvim.org/).

Implementation Steps for the Decision Framework

Step 1: Initial Assessment

1. Confirm CAD diagnosis using Favrot's criteria after excluding other pruritic dermatoses
2. Document baseline PVAS and CADESI-4 scores
3. Collect cytology from affected skin to identify secondary infections
4. Assess owner preferences, compliance factors, and financial constraints
5. Review medical history for contraindications to specific therapies

Step 2: Select First-Line Therapy

1. Use the decision algorithm based on speed of onset needed and patient factors
2. Discuss treatment options with owner including expected onset, dosing, adverse effects, and monitoring requirements
3. Prescribe selected therapy with clear instructions for administration
4. Schedule recheck visit in 2-4 weeks

Step 3: Monitor and Adjust

1. At each recheck, record PVAS and CADESI-4 scores
2. Assess for adverse effects and secondary infections
3. Adjust therapy based on response and tolerability
4. Consider adding ASIT for disease modification if not already initiated

Step 4: Establish Maintenance Protocol

1. Determine the minimum effective dose and frequency for each medication
2. Develop a written flare management plan
3. Schedule routine monitoring visits every 3-6 months
4. Perform laboratory monitoring as indicated for each medication

Step 5: Long-Term Surveillance

1. Monitor for adverse effects of long-term therapy
2. Reassess ASIT response at 6 and 12 months
3. Adjust therapy based on seasonal allergen exposure
4. Document all treatment changes and outcomes in medical record

Common Failure Patterns in Treatment Selection

Pattern 1: Inadequate initial assessment

• Failure to document baseline PVAS and CADESI-4 scores
• Failure to identify and treat secondary infections before initiating antipruritic therapy
• Failure to exclude food allergy before diagnosing CAD

Pattern 2: Inappropriate drug selection

• Using glucocorticoids as long-term monotherapy
• Selecting oclacitinib in dogs with history of seizures or demodicosis
• Selecting cyclosporine when rapid pruritus control is needed

Pattern 3: Inadequate monitoring

• Failure to perform recommended laboratory monitoring
• Failure to document treatment response with objective scoring tools
• Failure to recognize and address adverse effects early

Pattern 4: Poor owner communication

• Inadequate explanation of expected onset of action
• Failure to discuss long-term monitoring requirements
• Inadequate instruction on flare management

Safety Context for Long-Term Therapy

The World Organisation for Animal Health provides guidelines for responsible use of veterinary pharmaceuticals in chronic disease management (WOAH: www.woah.org/en/what-we-do/animal-health-and-welfare). Long-term antipruritic therapy requires ongoing risk-benefit assessment.

Oclacitinib safety monitoring:

• Complete blood count, serum biochemistry, and urinalysis every 6-12 months
• Urine culture if clinical signs of urinary tract infection
• Monitor for skin masses, papillomas, and demodicosis
• Thyroid monitoring if clinical signs of hypothyroidism develop
• Cortisol testing if clinical signs of hypoadrenocorticism develop

The case report of polyglandular autoimmune syndrome in a dog following long-term oclacitinib therapy recommends regular hormonal monitoring and careful dose adjustments (Frontiers in Veterinary Science: 10.3389/fvets.2025.1535272).

Glucocorticoid safety monitoring:

• Urinalysis and urine culture every 3-6 months
• Monitor body weight, muscle condition, and coat quality
• Blood glucose monitoring if clinical signs of diabetes mellitus
• ACTH stimulation test if clinical signs of hyperadrenocorticism

Cyclosporine safety monitoring:

• Complete blood count and serum biochemistry every 6-12 months
• Oral examination for gingival hyperplasia at each visit
• Monitor for papillomas and other skin masses

Lokivetmab safety monitoring:

• Pruritus assessment at each injection visit
• Monitor for injection site reactions
• No routine laboratory monitoring required

Frequently Asked Questions

What is the difference between atopic dermatitis and food allergy in dogs?

Atopic dermatitis is an environmental allergen-induced inflammatory skin disease, while food-induced atopic dermatitis (adverse food reaction) is triggered by dietary proteins. Both present with pruritus and similar lesion distribution. Diagnosis requires an 8-week elimination diet trial to differentiate. Food allergy can coexist with environmental allergies.

How long does allergen-specific immunotherapy take to work?

Initial improvement with ASIT is typically seen within 3-6 months, with maximal benefit at 9-12 months. Some dogs may show earlier response, while others require longer treatment. If no improvement is seen after 12 months, reformulation or alternative therapy should be considered.

Can oclacitinib be used long-term?

Oclacitinib is approved for long-term use in dogs with atopic dermatitis. However, prolonged use has been associated with potential adverse effects including urinary tract infections, demodicosis, papillomas, and neoplasia. Regular monitoring including complete blood count, serum biochemistry, and urinalysis every 6-12 months is recommended. Case reports have documented hemangiopericytoma, polyglandular autoimmune syndrome, and lingual lymphoma in dogs receiving long-term oclacitinib.

What is the role of topical therapy in CAD management?

Topical therapy is an important adjunctive component of CAD management. Antimicrobial shampoos treat secondary pyoderma and Malassezia dermatitis. Ceramide-containing products support skin barrier function. Topical glucocorticoid sprays provide localized anti-inflammatory effect. Topical therapy can reduce reliance on systemic medications.

How often should CADESI-4 scoring be performed?

CADESI-4 scoring should be performed at initial diagnosis, at each recheck visit during treatment adjustment (every 2-4 weeks), and at routine monitoring visits (every 3-6 months). Regular scoring provides objective documentation of disease severity and treatment response.

What are the indications for referral to a veterinary dermatologist?

Referral is indicated when diagnosis is uncertain, response to treatment is inadequate after 6 months, adverse effects limit treatment options, severe or refractory disease is present, or advanced diagnostic testing (IDT, skin biopsy) or specialized treatment (rush immunotherapy, allergen extract formulation) is needed.

Can CAD be cured?

CAD is a chronic, genetically predisposed disease with no cure. Management focuses on controlling pruritus, reducing skin lesions, preventing flares, and improving quality of life. Allergen-specific immunotherapy can modify the disease course and reduce reliance on symptomatic medications.

What is the difference between intradermal testing and serum IgE testing?

Intradermal testing (IDT) involves injecting allergen extracts intradermally and assessing wheal formation. IDT requires specialized training and equipment. Serum IgE testing measures allergen-specific IgE antibodies in blood. Both methods identify allergens for immunotherapy. IDT is considered the reference standard, but serum testing is more accessible. Results may not correlate between the two methods.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Dog Allergy Home Remedies
• Dog Allergy Remedies Home Remedies

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification.. BMC veterinary research, 2015.
• Diagnosis and Treatment of Canine Acral Lick Dermatitis.. The Veterinary clinics of North America. Small animal practice, 2019.
• Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs.. Journal of the American Veterinary Medical Association, 2019.
• Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.. Veterinary dermatology, 2025.
• Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs.. Veterinary dermatology, 2014.
• Introduction to the ICADA 2023 canine atopic dermatitis pathogenesis review articles and updated definition.. Veterinary dermatology, 2024.
• Case Report of Hemangiopericytoma Development After Prolonged Use of Oclacitinib Maleate in a Dog with Atopic Dermatitis and Iatrogenic Hyperadrenocorticism. International Journal of Zoology and Animal Biology, 2024.
• Comparative evaluation of therapeutic efficacy of prednisolone and oclacitinib in amelioration of canine atopic dermatitis in Indian dog population. Indian Journal of Animal Health, 2026.
• A case of lingual lymphoma in a dog treated with oclacitinib. Journal of Veterinary Medical Science, 2025.
• Case Report: The potential association with polyglandular autoimmune syndrome in a dog following long-term oclacitinib therapy. Frontiers in Veterinary Science, 2025.
• Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey. Animals, 2024.
• Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis. Veterinary Immunology and Immunopathology, 2004.
• Food allergen-specific sublingual immunotherapy modulates peripheral T cell responses of dogs with adverse food reactions. Veterinary Immunology and Immunopathology, 2019.
• Effect of immunotherapy on the serum concentrations of allergen-specific IgG antibodies in dog sera. Veterinary Immunology and Immunopathology, 1989.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.